A multicenter prospective study of the efficacy and safety of combined immunosuppressive therapy with high-dose glucocorticoid, tacrolimus, and cyclophosphamide in interstitial lung diseases accompanied by anti-melanoma differentiation-associated gene 5-positive dermatomyositis
Arthritis & Rheumatology Sep 25, 2019
Tsuji H, Nakashima R, Hosono Y, et al. - In view of the often rapid progression and association with poor prognosis of interstitial lung disease (ILD) accompanied by anti-melanoma differentiation-associated gene 5 (MDA5)-positive dermatomyositis (DM), researchers evaluated a combined immunosuppressive regimen for its efficacy and safety in treating anti-MDA5-positive DM with ILD. They treated 29 Japanese patients with newly onset anti-MDA5-positive DM with ILD with a regimen of high-dose glucocorticoids (GC), tacrolimus, and intravenous cyclophosphamide. They used plasmapheresis in cases where worsening occurred following initiation of the regimen. They observed significantly higher 6-month survival in the combined immunosuppressive regimen group vs the step-up treatment group. Outcomes support the efficacy of a combined immunosuppressive regimen for anti-MDA5-positive DM with ILD. In intractable disease, plasmapheresis seemed valuable for achieving the additional effect. They recommended careful monitoring of opportunistic infections during treatment.
Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
-
Exclusive Write-ups & Webinars by KOLs
-
Daily Quiz by specialty
-
Paid Market Research Surveys
-
Case discussions, News & Journals' summaries